Top White House scientist focused on Covid-19 has sought to step up pressure on Moderna, saying pharmaceutical giant needs to step up to deliver more of its Covid vaccine -19 in the world in the urgent race to bring the pandemic under control. While public health experts have called on Moderna to increase its production and distribution of its vaccine to low- and middle-income countries, or to share their proprietary technology, for a time, the remarks of Dr David Kessler - scientific director of thThe White House Covid-19 Response Team - marks an escalation in the Biden administration's public comments on the issue. We expect Moderna to grow stronger as a business. We expect - we asked them, they need to become a business and join other businesses, such as Pfizer, and provide to COVAX (Covid-19 Vaccines Global Access, the global vaccine sharing program) doses for AMC92 (the COVAX Advance Market Commitment for 92 low-and middle-income countries) at non-profit prices at a quantity - substantial doses that will help close that gap Kessler said Wednesday in a panel with the Law and Political Economy Project on immunization around the world. He continued, There is very substantial additional capacitythe in Moderna which was invested. Now the question is to make this commitment at a non-profit price and in substantial quantities, because not to do so would be unreasonable in my opinion. Kessler's comments come after the Biden administration pledged to dramatically increase the amount of Covid-19 vaccines it sends to foreign countries next year, President Joe Biden announcing last month the United States would purchase an additional 500 million Pfizer vaccines for low- and lower-middle-income countries around the world in more than the 500 million doses that the United States had already pledged to share. The majority of the doses the administration has shipped overseas so far are Pfizer, although Biden announced in June that 20 million doses of a combination of Moderna, Pfizer and Johnson & Johnson vaccines would be sent at theforeigner. Find out more CEO of Moderna Stephane Bancel a said in a letter to investors last week that Moderna 's goal is to help protect as many people as possible around the world, noting that the company has a strategy in five pillars to increase access, including plans to build a production facility in Africa, its intention not to enforce the patents related to Covid-19 and to invest in its capacity to deliver an additional 1 billion doses in the low-income country in 2022. And Tuesday, Moderna announced that COVAX has purchased an additional 176.5 million doses of its vaccine, of which 116.5 million doses are expected to be delivered in the first quarter of 2022 and 60 million doses are expected to be delivered in the secondQuarter 2022. But Dr Tom Frieden, former head of the US Centers for Disease Control and Prevention, is among the top experts repeatedly calling on Pfizer and Moderna to transfer their technology to other manufacturers to boost production and ibution distribution worldwide. Pfizer and Moderna have made fundamental mistakes that must be corrected or their reputation for this work will be irreparably tarnished and, more importantly, millions of lives will be put at risk. First, Pfizer and Moderna have focused on selling expensive doses to rich countries and have done little or nothing to increase production to meet global needs, Frieden said in a series of tweets earlier this month. He continued: This has led to the shocking and unacceptable situation in which wewe currently find. More than 6 billion doses have been administered worldwide, less than 4% to people in low-income countries. Not only is this a moral failure, but it is also epidemiologically perilous - fewer people vaccinated globally, this means that new, higher risk variants will emerge, which are more contagious or escape our control. immunity, whether from vaccines or infection or both. Kessler said Wednesday that the Biden administration had met with several leaders at Moderna in recent days to press them on the issue. We can't wait. We don 't have months to wait. I think we asked the question, we met, I say it here, we met Moderna board members, not just the CEO, we met Moderna chairman, board members administration of the last few days. They understand what we expect, he said. The US government, he said, hasn't made a decision on, you know, what that would do, in depending on the answer, but we are waiting for the answer ... but I can assure you that everyone is committed to lowering the doses and to middle-income countries as soon as possible. He praised Pfizer on its history and said he had no doubt that the company would meet its own global vaccine sharing commitments at cost. But he was much less confident in Moderna's ability to do so. , adding: Moderna can speak for itself. We had very, very intense discussions with Moderna. Pressed by moderator of the panel on why the administration is not exerting more influence over Moderna, Kess ler said: “I think these companies understand our authoritees and understand that we wouldn't be afraid to use them. -for-profit pricing as a substantial basis for bridging this gap. Kessler pointed to a specific request from the US government to do so, and warned: They understand our authorities. John CNN's Bonifield contributed to this report.